Free tool
FAERS Monitor: Bosulif
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217729 or its brand name (Bosulif, Bosutinib Monohydrate). Reports on generic versions are filed under their own applications.
Reports
8,981
Serious
5,051
56% of reports
Hospitalization
1,932
Death reported
799
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea2,078
- nausea1,020
- fatigue728
- vomiting544
- death538
- rash492
- pleural effusion458
- neoplasm progression373
- dyspnoea364
- headache339
- off label use330
- drug intolerance318
- malaise298
- drug ineffective280
- abdominal pain267
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 7 |
| 2012 | 60 |
| 2013 | 270 |
| 2014 | 398 |
| 2015 | 540 |
| 2016 | 504 |
| 2017 | 575 |
| 2018 | 697 |
| 2019 | 966 |
| 2020 | 865 |
| 2021 | 817 |
| 2022 | 851 |
| 2023 | 993 |
| 2024 | 737 |
| 2025 | 484 |
| 2026 | 207 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,178 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 373 | 25.4 | 23.0 | 8,636 |
| pleural effusionSignal | 458 | 17.8 | 16.2 | 7,189 |
| drug intoleranceSignal | 318 | 7.7 | 6.9 | 1,859 |
| diarrhoeaSignal | 2,078 | 7.6 | 7.3 | 12,158 |
| nauseaSignal | 1,020 | 3.0 | 2.9 | 1,429 |
| vomitingSignal | 544 | 2.7 | 2.5 | 599 |
| abdominal painSignal | 267 | 2.7 | 2.4 | 285 |
| rashSignal | 492 | 2.6 | 2.4 | 512 |
| fatigueSignal | 728 | 2.2 | 2.0 | 488 |
| malaise | 298 | 1.6 | 1.4 | 66 |
| dyspnoea | 364 | 1.5 | 1.4 | 63 |
| death | 538 | 1.5 | 1.3 | 82 |
| headache | 339 | 1.3 | 1.1 | 19 |
| off label use | 330 | 0.9 | 0.8 | 5 |
| drug ineffective | 280 | 0.5 | 0.4 | 151 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.